NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma


Journal of Translational Medicine201816:179
https://doi.org/10.1186/s12967-018-1552-1
© The Author(s) 2018
• Received: 8 June 2018
• Accepted: 19 June 2018
• Published: 29 June 2018

The original article was published in Journal of Translational Medicine 2018 16:142

Correction to: J Transl Med (2018) 16:142 https://doi.org/10.1186/s12967-018-1507-6

Following publication of the original article [1], the authors reported an error in the spelling of one of the author names. In this Correction the incorrect and correct author names are indicated and the author name has been updated in the original publication. The authors also reported an error in the Methods section of the original article. In this Correction the incorrect and correct versions of the affected sentence are indicated. The original article has not been updated with regards to the error in the Methods section.
Incorrect author name upon publication:
• Tobias Walpert
The correct author name:
• Tobias Walbert
The affected sentence in the Methods section upon publication, with the error marked in bold:
• In general, approximately 2 g of tumor tissue was needed to produce the full ten doses for the 36-month treatment and follow-up schedule. The vaccine was aliquoted in individual doses and cryopreserved at?<?150 °C [22].
The corrected sentence, with the corrected temperature marked in bold:
• In general, approximately 2 g of tumor tissue was needed to produce the full ten doses for the 36-month treatment and follow-up schedule. The vaccine was aliquoted in individual doses and cryopreserved at?<?-?150 °C [22].
The reference which is cited in the above sentence can be reviewed in the original article.